A Phase Ib Study of VK-2019 in Patients with Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs VK 2019 (Primary)
- Indications Diffuse large B cell lymphoma; Epstein-Barr virus infections
- Focus Adverse reactions
- 29 Jan 2025 New trial record